Agreement to sell Agilex Biolabs to Novotech

Key points

• Sale of Agilex Biolabs for A$160 million
• Expected completion during H2 FY 2027
• Healius to remain focused on Pathology business

Full summary

Healius Ltd (ASX: HLS) has entered into a binding agreement to sell its wholly owned subsidiary Agilex Biolabs to Novotech Health Holdings Pte Ltd for an enterprise value of A$160 million. The transaction, which is expected to result in cash proceeds of approximately $155 million, is anticipated to complete during H2 FY 2027, subject to customary conditions. The sale aims to unlock value for Healius shareholders and support the focus on the growth of its core Pathology business. Healius does not expect to incur any tax in relation to the Transaction.